Depakote ER in Bipolar Depression

Phase 4 Completed 28 enrolled Stanford University Abbott · collab National Alliance for Research on Schizophrenia and Depression · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to examine the safety and efficacy of Depakote ER in bipolar depression and to evaluate metabolic and GABA changes with Depakote ER administration using PET and MRI/MRS brain imaging techniques.

Timeline

Start: 2004-01
Primary completion: 2009-01
Completion: 2009-01

Publications

Results Wang PW, Nowakowska C, Chandler RA, Hill SJ, Nam JY, Culver JL, Keller KL, Ketter TA. Divalproex extended-release in acute bipolar II depression. J Affect Disord. 2010 Jul;124(1-2):170-3. doi: 10.1016/j.jad.2009.10.021.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Divalproex Sodium	Small molecule	1500 mg	—

Depakote ER in Bipolar Depression

Summary

Timeline

Publications

Drugs

Indications